Antoni Wiedlocha funded by the EEA Poland-Norway grants
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
From the National Centre for Research and Development in Poland:
Published in Level 2 journals, first or last author from Oslo University Hospital.
Gjølberg TT, Wik JA, Johannessen H, Krüger S, Bassi N, Christopoulos PF, Bern M, Foss S, Petrovski G, Moe MC, Haraldsen G, Fosse JH, Skålhegg BS, Andersen JT, Sundlisæter E(2023) Antibody blockade of Jagged1 attenuates choroidal neovascularization Nat Commun, 14(1), 3109 DOI 10.1038/s41467-023-38563-w, PubMed 37253747
Skaane P(2023) Interval and Successive-Round Cancers after Digital Breast Tomosynthesis Screening: We Still Need Convincing Results regarding Beneficial Evidence on Long-term Outcomes Radiology, 307(5), e230964 DOI 10.1148/radiol.230964, PubMed 37249434
Tunold JA, Tan MMX, Koga S, Geut H, Rozemuller AJM, Valentino R, Sekiya H, Martin NB, Heckman MG, Bras J, Guerreiro R, Dickson DW, Toft M, van de Berg W, Ross OA, Pihlstrøm L(2023) Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease Brain(in press) DOI 10.1093/brain/awad183, PubMed 37247383